Most Popular Articles

*CYP3A4**22 and *CYP3A5**3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

Kitzmiller, Joseph P.; Luzum, Jasmine A.; Baldassarre, Damiano; More

Pharmacogenetics and Genomics. 24(10):486-491, October 2014.

Open

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

van der Wouden, Cathelijne H.; Böhringer, Stefan; Cecchin, Erika; More

Pharmacogenetics and Genomics. 30(6):131-144, August 2020.

Open

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria

St Jean, Pamela L.; Koh, Gavin C.K.W.; Breton, John J.; More

Pharmacogenetics and Genomics. 30(7):161-165, September 2020.

Open
SDC

PharmGKB summary: very important pharmacogene information for CYP1A2: Erratum

Pharmacogenetics and Genomics. 29(9):224, November 2019.

Free

Valproic acid pathway: pharmacokinetics and pharmacodynamics

Ghodke-Puranik, Yogita; Thorn, Caroline F.; Lamba, Jatinder K.; More

Pharmacogenetics and Genomics. 23(4):236-241, April 2013.

Dietary intake alters gene expression in colon tissue: possible underlying mechanism for the influence of diet on disease

Pellatt, Andrew J.; Slattery, Martha L.; Mullany, Lila E.; More

Pharmacogenetics and Genomics. 26(6):294-306, June 2016.

Open
SDC

Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with *HLA-B**13: 01 allele in the Thai population

Tempark, Therdpong; Satapornpong, Patompong; Rerknimitr, Pawinee; More

Pharmacogenetics and Genomics. 27(12):429-437, December 2017.

Pharmacogenetic analysis of belimumab fails to identify robust genetic predictors of efficacy in lupus

St Jean, Pamela L.; Roth, David A.; McCarthy, Linda C.; More

Pharmacogenetics and Genomics. 29(6):132-135, August 2019.

Open
SDC

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

Sistonen, Johanna; Sajantila, Antti; Lao, Oscar; More

Pharmacogenetics and Genomics. 17(2):93-101, February 2007.

Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes

Tshabalala, Sibongile; Choudhury, Ananyo; Beeton-Kempen, Natasha; More

Pharmacogenetics and Genomics. 29(7):167-178, September 2019.

Open
SDC

A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators

Yoo, Hyounggyoon; Chun Ji, Sang; Cho, Joo-Youn; More

Pharmacogenetics and Genomics. 31(3):68-73, April 2021.

Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation

Hu, Rong; Barratt, Daniel T.; Coller, Janet K.; More

Pharmacogenetics and Genomics. 29(1):9-17, January 2019.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics

Chan, Sze Ling; Samaranayake, Nilakshi; Ross, Colin J.D.; More

Pharmacogenetics and Genomics. 26(1):28-39, January 2016.

Open
SDC

CYP2D6 copy number distribution in the US population

Beoris, Michelle; Amos Wilson, Jean; Garces, Jorge A.; More

Pharmacogenetics and Genomics. 26(2):96-99, February 2016.

Open

Doxorubicin pathways: pharmacodynamics and adverse effects

Thorn, Caroline F.; Oshiro, Connie; Marsh, Sharon; More

Pharmacogenetics and Genomics. 21(7):440-446, July 2011.

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

Elens, Laure; Becker, Matthijs L.; Haufroid, Vincent; More

Pharmacogenetics and Genomics. 21(12):861-866, December 2011.

Influence of donor liver CYP3A420* loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

Gómez-Bravo, Miguel A.; Apellaniz-Ruiz, María; Salcedo, Magdalena; More

Pharmacogenetics and Genomics. 28(2):41-48, February 2018.

Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury

Lang, Carmen; Meier, Yvonne; Stieger, Bruno; More

Pharmacogenetics and Genomics. 17(1):47-60, January 2007.

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

Roy, Jean Nicholas; Barama, Azemi; Poirier, Charles; More

Pharmacogenetics and Genomics. 16(9):659-665, September 2006.

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study

Bousman, Chad A.; Müller, Daniel J.; Ng, Chee H.; More

Pharmacogenetics and Genomics. 27(1):1-6, January 2017.

Open
SDC

Ontogeny-related pharmacogene changes in the pediatric liver transcriptome

Meier, Richard; Bi, Chengpeng; Gaedigk, Roger; More

Pharmacogenetics and Genomics. 28(3):86-94, March 2018.

Open
SDC

The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis

Terrazzino, Salvatore; Quaglia, Marco; Stratta, Piero; More

Pharmacogenetics and Genomics. 22(8):642-645, August 2012.

Ethanol-metabolizing activities and isozyme protein contents of alcohol and aldehyde dehydrogenases in human liver: phenotypic traits of the ADH1B2* and ALDH22* variant gene alleles

Chiang, Chien-Ping; Lai, Ching-Long; Lee, Shiao-Pieng; More

Pharmacogenetics and Genomics. 26(4):184-195, April 2016.

Effects of KCNMB2 gene polymorphisms on ritodrine therapy outcomes in women with preterm labor

Yoon, Ha Young; Park, Jin Young; Yee, Jeong; More

Pharmacogenetics and Genomics. 30(6):124-130, August 2020.

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Lonjou, Christine; Borot, Nicolas; Sekula, Peggy; More

Pharmacogenetics and Genomics. 18(2):99-107, February 2008.

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

Iulio, Julia di; Fayet, Aurélie; Arab-Alameddine, Mona; More

Pharmacogenetics and Genomics. 19(4):300-309, April 2009.

Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon

Ferreira, Guilherme Motta Antunes; Ribeiro Elias, Anna Beatriz; Nascimento, Joabi; More

Pharmacogenetics and Genomics. 30(8):184-189, October 2020.

The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation

Nenonen, Hannah A.; Lindgren, Ida A.; Prahl, Alexandra S.; More

Pharmacogenetics and Genomics. 29(5):114-120, July 2019.

Open

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation

Leger, Paul; Chirwa, Sanika; Nwogu, Jacinta N.; More

Pharmacogenetics and Genomics. 28(1):1-6, January 2018.

Open

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A16* and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1

Oswald, Stefan; König, Jörg; Lütjohann, Dieter; More

Pharmacogenetics and Genomics. 18(7):559-568, July 2008.

PharmGKB summary: sertraline pathway, pharmacokinetics

Huddart, Rachel; Hicks, J. Kevin; Ramsey, Laura B.; More

Pharmacogenetics and Genomics. 30(2):26-33, February 2020.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Open

Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily

Mackenzie, Peter I.; Walter Bock, Karl; Burchell, Brian; More

Pharmacogenetics and Genomics. 15(10):677-685, October 2005.

Codeine and morphine pathway

Thorn, Caroline F.; Klein, Teri E.; Altman, Russ B.

Pharmacogenetics and Genomics. 19(7):556-558, July 2009.

NUDT15 genotype distributions in the Korean population

Kim, Hyoung-Tae; Choi, Rihwa; Won, Hong-Hee; More

Pharmacogenetics and Genomics. 27(5):197-200, May 2017.

PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics

Mitra-Ghosh, Taraswi; Callisto, Samuel P.; Lamba, Jatinder K.; More

Pharmacogenetics and Genomics. 30(4):81-90, June 2020.

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Hung, Shuen-Iu; Chung, Wen-Hung; Jee, Shiou-Hwa; More

Pharmacogenetics and Genomics. 16(4):297-306, April 2006.

Selective serotonin reuptake inhibitors pathway

Sangkuhl, Katrin; Klein, Teri E.; Altman, Russ B.

Pharmacogenetics and Genomics. 19(11):907-909, November 2009.

Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand

Karuna, Narainrit; Tragulpiankit, Pramote; Mahasirimongkol, Surakameth; More

Pharmacogenetics and Genomics. 30(4):73-80, June 2020.

Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study

Barratt, Daniel T.; Bandak, Benedikte; Klepstad, Pål; More

Pharmacogenetics and Genomics. 24(4):185-194, April 2014.

Combined effects of *CYP3A5**1, *POR**28, and *CYP3A4**22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients

Kuypers, Dirk R.J.; de Loor, Henriette; Naesens, Maarten; More

Pharmacogenetics and Genomics. 24(12):597-606, December 2014.

Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues

Bièche, Ivan; Narjoz, Cèline; Asselah, Tarik; More

Pharmacogenetics and Genomics. 17(9):731-742, September 2007.

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

Open
SDC

St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways

Krusekopf, Solveigh; Roots, Ivar

Pharmacogenetics and Genomics. 15(11):817-829, November 2005.

Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes

Fukami, Tatsuki; Nakajima, Miki; Maruichi, Taiga; More

Pharmacogenetics and Genomics. 18(10):911-920, October 2008.

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

Fukudo, Masahide; Yano, Ikuko; Yoshimura, Atsushi; More

Pharmacogenetics and Genomics. 18(5):413-423, May 2008.

Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors

Mirza, Nasir S.; Alfirevic, Ana; Jorgensen, Andrea; More

Pharmacogenetics and Genomics. 21(5):297-302, May 2011.

Cost-effectiveness analysis of *HLA-B**58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in a Malaysian population

Chong, Huey Yi; Lim, Yi Heng; Prawjaeng, Juthamas; More

Pharmacogenetics and Genomics. 28(2):56-67, February 2018.

PharmGKB summary: ibuprofen pathways

Mazaleuskaya, Liudmila L.; Theken, Katherine N.; Gong, Li; More

Pharmacogenetics and Genomics. 25(2):96-106, February 2015.

JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity

Schimek, Vanessa; Björn, Niclas; Pellé, Lucia; More

Pharmacogenetics and Genomics. 31(3):60-67, April 2021.

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2

McDonagh, Ellen M.; Boukouvala, Sotiria; Aklillu, Eleni; More

Pharmacogenetics and Genomics. 24(8):409-425, August 2014.

Some molecular effectors of antidepressant action of quetiapine revealed by DNA microarray in the frontal cortex of anhedonic rats

Orsetti, Marco; Brisco, Fabio Di; Rinaldi, Maurizio; More

Pharmacogenetics and Genomics. 19(8):600-612, August 2009.

A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia

Itokawa, Masanari; Yamada, Kazuo; Yoshitsugu, Kiyoshi; More

Pharmacogenetics. 13(5):271-278, May 2003.

Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients

Kurzawski, Mateusz; Malinowski, Damian; Dziewanowski, Krzysztof; More

Pharmacogenetics and Genomics. 27(10):372-377, October 2017.

Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety

Tucci, Joseph D.; Pumuye, Paul P.; Helsby, Nuala A.; More

Pharmacogenetics and Genomics. 28(6):153-164, June 2018.

SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren

Tapaninen, Tuija; Karonen, Tiina; Backman, Janne T.; More

Pharmacogenetics and Genomics. 23(1):19-24, January 2013.

Free

Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients

Jessel, Chaten D.; Mostafa, Sam; Potiriadis, Maria; More

Pharmacogenetics and Genomics. 30(7):145-152, September 2020.

Discovery of new potentially defective alleles of human CYP2C9

Blaisdell, Joyce; Jorge-Nebert, Lucia F; Coulter, Sherry; More

Pharmacogenetics. 14(8):527-537, August 2004.

Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population

Saksit, Niwat; Tassaneeyakul, Wichittra; Nakkam, Nontaya; More

Pharmacogenetics and Genomics. 27(7):255-263, July 2017.

Thiopurine pathway

Zaza, Gianluigi; Cheok, Meyling; Krynetskaia, Natalia; More

Pharmacogenetics and Genomics. 20(9):573-574, September 2010.

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer

Li, Liang; Zhang, Jian-Wei; Jenkins, Gregory; More

Pharmacogenetics and Genomics. 26(12):527-537, December 2016.

Open
SDC

The relevance of the individual screening for genetic variants in predicting ovarian response

Lledó, Belén; Llácer, Joaquín; Blanco, Laura; More

Pharmacogenetics and Genomics. 29(9):216-223, November 2019.

Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles

Zarca, Kevin; Chansavang, Albain; Loriot, Marie-Anne; More

Pharmacogenetics and Genomics. 30(8):175-183, October 2020.

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

Lötsch, Jörn; von Hentig, Nils; Freynhagen, Rainer; More

Pharmacogenetics and Genomics. 19(6):429-436, June 2009.

Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design

Stone, Isabella B.; Green, Jessica A.E.M.; Koefoed, Andrew W.; More

Pharmacogenetics and Genomics. 31(4):83-88, June 2021.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver

Girard, Hugo; Court, Michael H; Bernard, Olivier; More

Pharmacogenetics. 14(8):501-515, August 2004.

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Lubomirov, Rubin; di Iulio, Julia; Fayet, Aurélie; More

Pharmacogenetics and Genomics. 20(4):217-230, April 2010.

Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation

Behre, Hermann M.; Greb, Robert R.; Mempel, Andrea; More

Pharmacogenetics and Genomics. 15(7):451-456, July 2005.

The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease

Dideberg, Vinciane; Théâtre, Emilie; Farnir, Frédéric; More

Pharmacogenetics and Genomics. 16(10):727-734, October 2006.

SiRNA gene therapy using albumin as a carrier

Malhotra, Anshoo; Mittal, Bhagwant Rai

Pharmacogenetics and Genomics. 24(12):582-587, December 2014.

Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma

Choudhary, Dharamainder; Jansson, Ingela; Sarfarazi, Mansoor; More

Pharmacogenetics and Genomics. 18(8):665-676, August 2008.

CYP3A51*-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

Goto, Maki; Masuda, Satohiro; Kiuchi, Tetsuya; More

Pharmacogenetics. 14(7):471-478, July 2004.

Influence of CMTM8 polymorphisms on lung cancer susceptibility in the Chinese Han population

Wu, Jiamin; Sun, Yao; Xiong, Zichao; More

Pharmacogenetics and Genomics. 31(4):89-95, June 2021.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

Chen, Ying; Li, Shuanglian; Brown, Chaline; More

Pharmacogenetics and Genomics. 19(7):497-504, July 2009.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi; Wilkinson, Grant R.; Nutescu, Edith A.; More

Pharmacogenetics and Genomics. 16(2):101-110, February 2006.

Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients

Djebli, Nassim; Picard, Nicolas; Rérolle, Jean-Philippe; More

Pharmacogenetics and Genomics. 17(5):321-330, May 2007.

Pharmacokinetic and pharmacodynamic basis for partial protection against alcoholism in Asians, heterozygous for the variant *ALDH2**2 gene allele

Peng, Giia-Sheun; Chen, Yi-Chyan; Tsao, Tien-Ping; More

Pharmacogenetics and Genomics. 17(10):845-855, October 2007.

HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia

Low, Dyoi E; Nurul-Aain, Ahmad Fauzi; Tan, Wooi Chiang; More

Pharmacogenetics and Genomics. 30(7):153-160, September 2020.

Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor

Carrasquer, Alex; Nebane, Nstang M.; Williams, Walter M.; More

Pharmacogenetics and Genomics. 20(3):157-166, March 2010.

Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4)

Urban, Thomas J.; Yang, Chen; Lagpacan, Leah L.; More

Pharmacogenetics and Genomics. 17(9):773-782, September 2007.

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Pasanen, Marja K.; Neuvonen, Mikko; Neuvonen, Pertti J.; More

Pharmacogenetics and Genomics. 16(12):873-879, December 2006.

Functional analysis of human thromboxane synthase polymorphic variants

Chen, Chung-Ying K.; Poole, Elizabeth M.; Ulrich, Cornelia M.; More

Pharmacogenetics and Genomics. 22(9):653-658, September 2012.

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy

Huang, Ming-Yii; Huang, Meng-Lin; Chen, Ming-Jenn; More

Pharmacogenetics and Genomics. 21(1):18-25, January 2011.

Influence of mutations associated with Gilbert and Crigler–Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates

Udomuksorn, Wandee; Elliot, David J.; Lewis, Benjamin C.; More

Pharmacogenetics and Genomics. 17(12):1017-1029, December 2007.

Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution

Doehring, Alexandra; Hentig, Nils von; Graff, Jochen; More

Pharmacogenetics and Genomics. 19(6):407-414, June 2009.

Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers

Tan, Eng-King; Chua, Eva; Fook-Chong, Stephanie M.; More

Pharmacogenetics and Genomics. 17(11):1001-1005, November 2007.

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

Lee, Janet S.; Wang, Jianmei; Martin, Mitchell; More

Pharmacogenetics and Genomics. 21(7):365-374, July 2011.

Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation

Menon, Saras; Lea, Rod A.; Roy, Bishakha; More

Pharmacogenetics and Genomics. 22(10):741-749, October 2012.

ALDH22* but not ADH1B2* is a causative variant gene allele for Asian alcohol flushing after a low-dose challenge: correlation of the pharmacokinetic and pharmacodynamic findings

Peng, Giia-Sheun; Chen, Yi-Chyan; Wang, Ming-Fang; More

Pharmacogenetics and Genomics. 24(12):607-617, December 2014.

Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative

Zajic, Stefan C.; Jarvis, Joseph P.; Zhang, Pan; More

Pharmacogenetics and Genomics. 29(3):49-57, April 2019.

PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses

Mazaleuskaya, Liudmila L.; Sangkuhl, Katrin; Thorn, Caroline F.; More

Pharmacogenetics and Genomics. 25(8):416-426, August 2015.

Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis

Tammimäki, Anne; Männistö, Pekka T.

Pharmacogenetics and Genomics. 22(9):673-691, September 2012.

Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia

Lopez-Lopez, Elixabet; Ballesteros, Javier; Piñan, Maria A.; More

Pharmacogenetics and Genomics. 23(2):53-61, February 2013.

Very important pharmacogene summary ADRB2

Litonjua, Augusto A.; Gong, Li; Duan, Qing Ling; More

Pharmacogenetics and Genomics. 20(1):64-69, January 2010.

4β-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians

Diczfalusy, Ulf; Miura, Jun; Roh, Hyung-Keun; More

Pharmacogenetics and Genomics. 18(3):201-208, March 2008.

Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy

Ufer, Mike; Mosyagin, Igor; Muhle, Hiltrud; More

Pharmacogenetics and Genomics. 19(5):353-362, May 2009.

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

Zhang, Jieying Eunice; Jorgensen, Andrea L.; Alfirevic, Ana; More

Pharmacogenetics and Genomics. 19(10):781-789, October 2009.

Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants

Schaeffeler, Elke; Fischer, Christine; Brockmeier, Dierk; More

Pharmacogenetics. 14(7):407-417, July 2004.

Login

Register for a free account

In Brief: